[go: up one dir, main page]

MX2014013839A - 5-amino[1,4]tiazinas como inhibidores de beta-secretasa 1 (bace 1). - Google Patents

5-amino[1,4]tiazinas como inhibidores de beta-secretasa 1 (bace 1).

Info

Publication number
MX2014013839A
MX2014013839A MX2014013839A MX2014013839A MX2014013839A MX 2014013839 A MX2014013839 A MX 2014013839A MX 2014013839 A MX2014013839 A MX 2014013839A MX 2014013839 A MX2014013839 A MX 2014013839A MX 2014013839 A MX2014013839 A MX 2014013839A
Authority
MX
Mexico
Prior art keywords
thiazines
bace
inhibitors
amino
present
Prior art date
Application number
MX2014013839A
Other languages
English (en)
Inventor
Thomas Woltering
Hans Hilpert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014013839A publication Critical patent/MX2014013839A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula I que tiene actividad inhibidora de BACE1, su manufactura, composiciones farmacéuticas que lo contienen y su uso como sustancias terapéuticamente activas. Los compuestos activos de la presente invención son útiles en el tratamiento terapéutico y/o profiláctico de, por ejemplo, la enfermedad de Alzheimer.
MX2014013839A 2012-05-24 2013-05-21 5-amino[1,4]tiazinas como inhibidores de beta-secretasa 1 (bace 1). MX2014013839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12169353 2012-05-24
PCT/EP2013/060352 WO2013174781A1 (en) 2012-05-24 2013-05-21 5-amino[1,4]thiazines as bace 1 inhibitors

Publications (1)

Publication Number Publication Date
MX2014013839A true MX2014013839A (es) 2015-02-04

Family

ID=48534350

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013839A MX2014013839A (es) 2012-05-24 2013-05-21 5-amino[1,4]tiazinas como inhibidores de beta-secretasa 1 (bace 1).

Country Status (21)

Country Link
US (1) US9273042B2 (es)
EP (1) EP2855469B1 (es)
JP (1) JP6251249B2 (es)
KR (1) KR20150014934A (es)
CN (1) CN104334554B (es)
AU (1) AU2013265376B2 (es)
BR (1) BR112014028813A2 (es)
CA (1) CA2872179A1 (es)
CL (1) CL2014003123A1 (es)
CO (1) CO7131369A2 (es)
CR (1) CR20140495A (es)
EA (1) EA026004B1 (es)
IL (1) IL235681A (es)
MA (1) MA37691B1 (es)
MX (1) MX2014013839A (es)
NZ (1) NZ702254A (es)
PE (1) PE20150021A1 (es)
PH (1) PH12014502541A1 (es)
SG (1) SG11201407575PA (es)
UA (1) UA113438C2 (es)
WO (1) WO2013174781A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103874496A (zh) * 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
US9096615B2 (en) 2013-07-30 2015-08-04 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
WO2015038446A1 (en) * 2013-09-13 2015-03-19 Merck Sharp & Dohme Corp. C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use
US9920072B2 (en) 2014-11-03 2018-03-20 Hoffmann-La Roche Inc. BACE1 inhibitors
US10047081B2 (en) * 2015-03-20 2018-08-14 Hoffman-La Roche Inc. BACE1 inhibitors
JP6895424B2 (ja) * 2015-08-12 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤
KR20210003872A (ko) 2018-04-27 2021-01-12 시오노기 앤드 컴파니, 리미티드 선택적 bace1 억제 활성을 갖는 테트라하이드로피라노옥사진 유도체
CN110467611B (zh) * 2018-05-11 2022-09-27 广东东阳光药业有限公司 亚氨基噻二嗪二氧化物衍生物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084199A (zh) * 2004-10-15 2007-12-05 阿斯利康(瑞典)有限公司 取代的氨基化合物及其用途
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
US8188079B2 (en) * 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20110065695A1 (en) * 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
MX2013011947A (es) 2011-04-13 2014-01-16 Merck Sharp & Dohme Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso.
CN103874496A (zh) * 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途

Also Published As

Publication number Publication date
CL2014003123A1 (es) 2015-02-27
CA2872179A1 (en) 2013-11-28
PE20150021A1 (es) 2015-01-28
MA37691A1 (fr) 2016-03-31
AU2013265376A1 (en) 2014-11-13
CR20140495A (es) 2014-12-01
IL235681A (en) 2017-10-31
JP6251249B2 (ja) 2017-12-20
PH12014502541B1 (en) 2015-01-21
CN104334554A (zh) 2015-02-04
IL235681A0 (en) 2015-02-01
US20150141413A1 (en) 2015-05-21
HK1201261A1 (en) 2015-08-28
MA37691B1 (fr) 2016-11-30
EA201492097A1 (ru) 2015-04-30
UA113438C2 (xx) 2017-01-25
EA026004B1 (ru) 2017-02-28
SG11201407575PA (en) 2014-12-30
EP2855469B1 (en) 2019-06-19
AU2013265376B2 (en) 2017-07-20
NZ702254A (en) 2016-08-26
BR112014028813A2 (pt) 2017-06-27
PH12014502541A1 (en) 2015-01-21
CO7131369A2 (es) 2014-12-01
WO2013174781A1 (en) 2013-11-28
EP2855469A1 (en) 2015-04-08
KR20150014934A (ko) 2015-02-09
CN104334554B (zh) 2017-10-31
US9273042B2 (en) 2016-03-01
JP2015517548A (ja) 2015-06-22

Similar Documents

Publication Publication Date Title
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
PH12013502156A1 (en) 1,3-oxazines as bace1 and/or bace2 inhibitors
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MX2013014007A (es) [1,3] oxazinas.
PH12013502090A1 (en) 1,3 oxazines as bace1 and/or bace2 inhibitors
PH12015502365B1 (en) Bace1 inhibitors
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
IN2012DN00766A (es)
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
MX2013008213A (es) N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
PH12017501668A1 (en) Bace1 inhibitors
MX365292B (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
MX2013002398A (es) Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators